Direkt zum Inhalt
Merck

1359404

USP

Levetiracetam

United States Pharmacopeia (USP) Reference Standard

Synonym(e):

(αS)-α-Ethyl-2-oxo-1-pyrrolidinacetamid, 2(S)-(2-Oxopyrrolidin-1-yl)-butyramid

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C8H14N2O2
CAS-Nummer:
Molekulargewicht:
170.21
MDL-Nummer:
UNSPSC-Code:
41116107
PubChem Substanz-ID:
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

levetiracetam

Hersteller/Markenname

USP

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

SMILES String

CC[C@H](N1CCCC1=O)C(N)=O

InChI

1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1

InChIKey

HPHUVLMMVZITSG-LURJTMIESA-N

Angaben zum Gen

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Levetiracetam USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Biochem./physiol. Wirkung

Levetiracetam ist ein Pyrrolidin mit antiepileptischer Wirkung. Stereoselektive Bindung von Levetiracetam ist auf synaptische Plasmamembranen im zentralen Nervensystem beschränkt, in peripherem Gewebe kommt es zu keiner Bindung. Levetiracetam hemmt das sogenannte "burst firing", ohne die normale neuronale Erregbarkeit zu beeinflussen.

Hinweis zur Analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Leider sind derzeit keine COAs für dieses Produkt online verfügbar.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Gashirai K Mbizvo et al.
The Cochrane database of systematic reviews, 9(9), CD001901-CD001901 (2012-09-14)
Epilepsy is an important neurological condition and drug resistance in epilepsy is particularly common in individuals with focal seizures. In this review, we summarise the current evidence regarding a new antiepileptic drug, levetiracetam, when used as add-on treatment for controlling
Benjamin W Y Lo et al.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 38(3), 475-486 (2011-04-26)
New evidence suggests that levetiracetam may be as effective as traditional agents, with better safety profile. To synthesize evidence regarding efficacy and tolerability of levetiracetam as first line, adjunctive or prophylactic antiepileptic agent. Study Selection & Data Extraction: Eligible studies
Brian Longo et al.
The Annals of pharmacotherapy, 43(10), 1692-1695 (2009-08-20)
To review data evaluating levetiracetam management of epilepsy during pregnancy. A literature search of PubMed (1966-June 2009) was performed using the terms pregnancy, epilepsy, levetiracetam, and anticonvulsants. Bibliographies of all articles retrieved were reviewed to identify additional relevant articles. All
Amy Z Crepeau et al.
Expert review of neurotherapeutics, 10(2), 159-171 (2010-02-09)
Levetiracetam was approved by the US FDA in 1999 after failing the traditional screening tests for antiepileptic drugs. In the 10 years since its introduction, it has become one of the first-line antiepileptic agents and has been evaluated in small
Vincenzo Belcastro et al.
Brain & development, 33(4), 289-293 (2010-07-16)
Several new antiepileptic drugs (AEDs) have been introduced for clinical use recently. These new AEDs, like the classic AEDs, target multiple cellular sites both pre- and postsynaptically. The use of AEDs as a possible neuroprotective strategy in brain ischemia is

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.